Lifevantage Corporation Common Stock (Delaware) (LFVN) Stock Price

LFVNStock

$6.00−33.11%52W

Market Cap$75.54M

P/E14.89x

PEG Ratio0.36

Div yield2.41%

Beta0.77

LFVN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)35.20%

Price vs S&P 500 (4W)-2.21%

PEG Ratio0.36

VGM Score54.50

P/E Ratio (Annual)14.89x

Indicated Dividend Yield (Annual)2.41%

P/CF (Annual)7.38x

Book Value / Share (Quarterly)$2.68

P/TBV (Annual)2.58x

Indicated Dividend (Annual)$0.20

Revenue Growth (3Y)-5.07%

Cash Flow / Share (Quarterly)$0.53

Payout Ratio (TTM)46.21%

Price vs S&P 500 (YTD)-14.52%

Gross Margin (TTM)77.56%

Net Profit Margin (TTM)2.78%

EPS (TTM)$0.40

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$0.40

Revenue Growth (5Y)-3.68%

EPS (Annual)$0.40

Dividend / Share (Annual)$0.19

ROI (Annual)15.10%

Gross Margin (Annual)77.56%

Net Profit Margin (5Y Avg)2.24%

Cash / Share (Quarterly)$1.19

P/E Basic Excl Extra (TTM)14.89x

Revenue Growth QoQ (YoY)-23.11%

EPS Growth (5Y)-15.04%

P/E Normalized (Annual)14.89x

ROA (Last FY)8.17%

Revenue Growth TTM (YoY)-20.10%

EBITD / Share (TTM)$0.70

ROE (5Y Avg)14.35%

Operating Margin (TTM)3.34%

Cash Flow / Share (Annual)$0.53

P/B Ratio2.25x

P/B Ratio (Quarterly)2.34x

Net Income / Employee (Annual)$21,900

EV / Revenue (TTM)0.33x

Net Interest Coverage (TTM)169.50x

ROA (TTM)8.21%

EPS Growth QoQ (YoY)-32.36%

EV / EBITDA (TTM)6.83x

EPS Incl Extra (Annual)$0.40

Current Ratio (Annual)1.89x

Quick Ratio (Quarterly)0.95x

3-Month Avg Trading Volume0.15M

52-Week Price Return-33.11%

EV / Free Cash Flow (Annual)9.09x

P/E Incl Extra (TTM)14.89x

Revenue / Employee (TTM)$787,000

Tangible BV / Share (Quarterly)$2.44

P/S Ratio (Annual)0.41x

Asset Turnover (Annual)2.94x

52-Week High$11.71

Operating Margin (5Y Avg)3.09%

EPS Excl Extra (Annual)$0.40

CapEx CAGR (5Y)-0.92%

Tangible BV CAGR (5Y)-3.28%

26-Week Price Return45.10%

Quick Ratio (Annual)0.95x

13-Week Price Return-3.23%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.89x

Enterprise Value$60.62M

Revenue / Share Growth (5Y)-1.37%

Asset Turnover (TTM)2.96x

Book Value / Share Growth (5Y)-0.15%

Revenue / Employee (Annual)$787,000

Inventory Turnover (Annual)2.22x

Pretax Margin (Annual)3.32%

Cash / Share (Annual)$1.19

3-Month Return Std Dev28.54%

Gross Margin (5Y Avg)79.69%

Net Income / Employee (TTM)$21,900

EBITDA CAGR (5Y)-15.88%

EBITDA Interim CAGR (5Y)-20.41%

ROE (Last FY)15.10%

Net Interest Coverage (Annual)115.62x

EPS Basic Excl Extra (Annual)$0.40

P/FCF (TTM)8.02x

Receivables Turnover (TTM)58.11x

EV / Free Cash Flow (TTM)9.09x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.40

Receivables Turnover (Annual)58.11x

ROI (TTM)15.25%

P/S Ratio (TTM)0.41x

Pretax Margin (5Y Avg)3.00%

Revenue / Share (Annual)$14.37

Tangible BV / Share (Annual)$2.44

Forward P/E18.45x

Free OCF CAGR (5Y)-11.85%

Price vs S&P 500 (52W)-48.64%

P/E Ratio (TTM)14.89x

EPS Growth TTM (YoY)-46.79%

Year-to-Date Return-2.60%

5-Day Price Return0.33%

EPS Normalized (Annual)$0.40

ROA (5Y Avg)6.97%

Net Profit Margin (Annual)2.78%

Month-to-Date Return-4.76%

Cash Flow / Share (TTM)$0.49

EBITD / Share (Annual)$0.70

EPS Growth (3Y)26.26%

Operating Margin (Annual)3.34%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)7.38x

ROI (5Y Avg)14.35%

P/E Excl Extra (TTM)14.89x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.40

P/TBV (Quarterly)2.58x

Payout Ratio (Annual)46.21%

P/B Ratio (Annual)2.34x

Dividend / Share (TTM)$0.19

Inventory Turnover (TTM)2.22x

Pretax Margin (TTM)3.32%

Book Value / Share (Annual)$2.68

Price vs S&P 500 (13W)-5.91%

Net Margin Growth (5Y)-13.86%

Dividend Yield (TTM)3.10%

Beta0.77x

P/FCF (Annual)11.32x

Revenue / Share (TTM)$14.56

ROE (TTM)15.25%

52-Week Low$3.90

vGradeB

gGradeD

mGradeB

vgmGradeC

LFVN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 27, 2026	$0.13	$0.11	-13.16%(-$0.02)
Q1 2026	May 6, 2026	$0.16	$0.12	-23.41%(-$0.04)
Q4 2025	Feb 4, 2026	$0.15	$0.15	+0.00%(+$0.00)
Q3 2025	Nov 4, 2025	$0.19	$0.18	-5.26%(-$0.01)
Q2 2025	Sep 4, 2025	$0.20	$0.17	-12.82%(-$0.02)

LFVN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LFVNLifevantage Corporation Common Stock (Delaware)	B	D	B	0.4x	-20.1%	77.6%	-15.0%	$6.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Lifevantage Corporation Common Stock (Delaware)

LifeVantage develops and distributes nutraceutical supplements and skincare products, including Protandim, LifeVantage TrueScience, Axio energy drinks, and PhysIQ. The company operates in ten countries across North America, Asia-Pacific, and Europe. Its products are positioned as scientifically-validated wellness solutions for health-conscious consumers.

LFVN Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.06

Revenue estimate$40.49M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

LFVN Insider Transactions

BuySep 15, 2026
LEWIS DARWIN K
Director
Shares: 976Value: $6,071
SellSep 14, 2026
CUNNINGHAM KRISTEN
Officer
Shares: 9,001Value: $55,649

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

FTLFFitLife Brands, Inc. Common StockPharmaceutical Preparations
ARQArq, Inc. Common StockIndustrial Chemicals
FSIFlexible Solutions International, Inc.Industrial Chemicals
PTHSPelthos Therapeutics Inc.Biological Products
OKYOOKYO Pharma Limited Ordinary SharesBiological Products
CRDFCardiff Oncology, Inc. Common StockBiological Products
CGTXCognition Therapeutics, Inc. Common StockBiological Products
CSBRChampions Oncology, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$3.90

High$11.71